Close Menu

SAN FRANCISCO (GenomeWeb) – Hong Kong startup Take2 Health, which said on Monday that it had licensed intellectual property from Grail to develop a noninvasive early detection test for nasopharyngeal carcinoma, aims to launch its first test in Hong Kong and parts of southern China within the next several months, according to cofounder Dennis Lo.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.